Oral contraceptive use and the risk of breast cancer

Mayo Clinic Proceedings

Volumn 83, Issue 1, 2008, Pages 86-91

  Casey, Petra M ^a   Cerhan, James R ^a   Pruthi, Sandhya ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; AROMATASE INHIBITOR; DESOGESTREL; DROSPIRENONE; ESTROGEN; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS LEVONORGESTREL; GLUCOSE; LEVONORGESTREL; LIPID; NORETHISTERONE ACETATE; NORGESTIMATE; ORAL CONTRACEPTIVE AGENT; PROGESTERONE DERIVATIVE; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

BREAST CANCER; BREAST CARCINOGENESIS; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; DISEASE ASSOCIATION; DRUG FORMULATION; HEADACHE; HIGH RISK PATIENT; HUMAN; MASTALGIA; NAUSEA; ORAL CONTRACEPTION; PATIENT COUNSELING; REVIEW; VENOUS THROMBOEMBOLISM;

EID: 37549017282     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/83.1.86     Document Type: Review

References (36)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007;57(1):43-66.
2. Clarke CA, Glaser SL, Uratsu CS, Selby JV, Kushi LH, Herrinton LJ. Recent declines in hormone therapy utilization and breast cancer incidence: clinical and population-based evidence [letter]. J Clin Oncol. 2006;24933):e49-e50.
3. Jemal A, Ward E, Thun MJ. Recent trends in breast cancer incidence rates by age and tumor characteristics among U.S. women. Breast Cancer Res. 2007;9(3):R28.
4. Ravdin PM, Cronin KA, Howlader N, et al. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med. 2007;356(16):1670-1674.
5. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-333.
6. Breen N, A Cronin K, Meissner HI, et al. Reported drop in mammography: is this cause for concern? Cancer. 2007;109912):2405-2409.
7. Berry DA, Cronin KA, Plevritis SK, et al, Cancer Intervention and Surveillance Modeling Network (CISNET) Collaborators. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005;353(17):1784-1792.
8. Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer. N Engl J Med. 2006;354(3):270-282.
9. Santen RJ, Yue W, Bocchinfuso W, et al. Estradiol-induced carcinogenesis via formation of genotoxic metabolites. In: Ingle JN, Dowsett M, eds. Advances in Endocrine Therapy of Breast Cancer: Proceedings of the 2003 Gleneagles Conference. New York, NY: Summit Communications; 2004:163-177.
10. Yager JD. Endogenous estrogens as carcinogens through metabolic activation. J Natl Cancer Inst Monogr. 2000;27:67-73.
11. McPherson K, Steel CM, Dixon JM. ABC of breast diseases: breast cancer-epidemiology, risk factors, and genetics. BMJ. 2000;321(7261):624-628.
12. Bensyl DM, Iuliano DA, Carter M, Santelli J, Gilbert BC. Contraceptive use - United States and territories, Behavioral Risk Factor Surveillance System, 2002. MMWR Surveill Summ. 2005;54(6):1-72.
13. Trussell J. Contraceptive efficacy. In: Hatcher RA, Trussell J, Stewart F, et al, eds. Contraceptive Technology. 17th ed. New York, NY: Ardent Media; 1998:779-844.
14. Implanon [package insert]. Roseland, NJ: Organon USA Inc; 2006.
15. Association of Reproductive Health Professionals. Extended regimen oral contraceptives. Harris Poll. June 14-17, 2002.
16. den Tonkelaar I, Oddens BJ. Preferred frequency and characteristics of menstrual bleeding in relation to reproductive status, oral contraceptive use, and hormone replacement therapy use. Contraception. 1999;59(6):357-362.
17. Miller L, Hughes JP. Continuous combination oral contraceptive pills to eliminate withdrawal bleeding: a randomized trial. Obstet Gynecol. 2003;101(4):653-661.
18. Cronin, M, Mohner S. Past oral contraception use does not negatively affect time to conception. Abstract presented at the Annual American College of Obsetricians and Gynecologists 55th Annual Clinical Meeting; San Diego, CA; May 7-9, 2007.
19. Burkman R. The evolution of oral contraceptives: 40 years of continuous improvement. Clinician. 2002;20:3-30.
20. Vercellini P, Frontino G, De Giorgi O, Pietropaolo G, Pasin R, Crosignani PG. Continuous use of an oral contraceptive for endometriosis-associated recurrent dysmenorrhea that does not respond to a cyclic pill regimen. Fertil Steril. 2003;80(3):560-563.
21. Parsey KS, Pong A. An open-label, multicenter study to evaluate Yasmin, a low-dose combination oral contraceptive containing drospirenone, a new progestogen. Contraception. 2000;61(2):105-111.
22. Tzourio C, Tehindrazanarivelo A, Iglésias S, et al. Case-control study of migraine and risk of ischaemic stroke in young women. BMJ. 1995;310(6983):830-833.
23. Steinauer, J, Autry AM. Extended cycle combined hormonal contraception. Obstet Gynecol Clin North Am. 2007;34:43-55.
24. Hoyert DL. Maternal mortality and related concepts. Vital Health Stat 3. 2007;33:1-13.
25. Mashchak CA, Lobo RA, Dozono-Takano R, et al. Comparison of pharmacodynamic properties of various estrogen formulations. Am J Obstet Gynecol. 1982;144(5):511-518.
26. International Agency for Research on Cancer. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Vol 91: Combined Estrogen-Progestogen Contraceptives and Combined Estrogen-Progestogen Menopausal Therapy. Lyon, France. In press.
27. Cogliano V, Grosse Y, Baan R, et al. Carcinogenicity of combined oestrogen-progestagen contraceptives and menopausal treatment. Lancet Oncol. 2005;6(8):552-553.
28. International Agency for Research on Cancer. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Vol 72: Hormonal Contraception and Post-menopausal Hormonal Therapy. Lyon, France:IARC; 1999.
29. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet. 1996;347(9017):1713-1727.
30. Kahlenborn C, Modugno F, Potter DM, Severs WB. Oral contraceptive use as a risk factor for premenopausal breast cancer: a meta-analysis. Mayo Clin Proc. 2006;81(10):1290-1302.
31. Marchbanks PA, McDonald JA, Wilson HG, et al. Oral contraceptives and the risk of breast cancer. N Engl J Med. 2002;346(26):2025-2032.
32. Wingo PA, Austin H, Marchbanks PA, et al. Oral contraceptives and the risk of death from breast cancer. Obstet Gynecol. 2007;110(4):793-800.
33. Grabrick DM, Hartmann LC, Cerhan JR, et al. Risk of breast cancer with oral contraceptive use in women with a family history of breast cancer. JAMA. 2000;284(14):1791-1798.
34. Narod SA, Dubé MP, Klijn J, et al. Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst. 2002;94(23):1773-1779.
35. Haile RW, Thomas DC, McGuire V, et al. BRCA1 and BRCA2 mutation carriers, oral contraceptive use, and breast cancer before age 50. Cancer Epidemiol Biomarkers Prev. 2006;15(10):1863-1870.
36. Brohet RM, Goldgar DE, Easton DF, et al. Oral contraceptives and breast cancer risk in the International BRCA1/2 Carrier Cohort Study: a report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating Group. J Clin Oncol. 2007;25(25):3831-3836. Epub 2007 Jul 16.